VXRT Share Price Performance
US$0.37
-0.22 (-37.36%)
88.9% undervalued intrinsic discount
US$3.33
Fair Value
Price US$0.37
AnalystConsensusTarget US$3.33
Fair ValueUS$3.33
Share Pricen/a
Vaxart, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
VXRT Community Narratives
AN
Fair Value US$3.33 88.9% undervalued intrinsic discount
Oral Vaccine Platform And Norovirus Opportunity Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Oral Vaccine Platform And Norovirus Opportunity Will Drive Long Term Upside Potential
Catalysts About Vaxart Vaxart develops oral tablet vaccines designed to generate both systemic and mucosal immunity against infectious diseases. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$3.33
88.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-34.98% p.a.
Profit Margin
16.03%
Future PE
177.4x
Price in 2028
US$4.13
Trending Discussion
Recently Updated Narratives
AN
Oral Vaccine Platform And Norovirus Opportunity Will Drive Long Term Upside Potential
Fair Value: US$3.33 88.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vaxart, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.21
- -20.83%
- -34.21%
- 13.1%
About VXRT
- Founded
- n/a
- Employees
- 105
- CEO
- WebsiteView website
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
